{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:07:43Z","timestamp":1771355263389,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.diagmicrobio.2016.10.010","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T10:42:47Z","timestamp":1476528167000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis"],"prefix":"10.1016","volume":"87","author":[{"given":"E.","family":"Cendejas-Bueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Forastiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gavald\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gomez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0005","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40265-014-0227-3","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications","volume":"74","author":"Autmizguine","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0015","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1128\/AAC.03252-14","article-title":"Posaconazole concentrations in human tissues after allogeneic stem cell transplantation","volume":"58","author":"Blennow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0020","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jit358","article-title":"Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis","volume":"208","author":"Campoli","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1469-0691.2011.03732.x","article-title":"HPLC\/UV or bioassay: two valid methods for posaconazole quantification in human serum samples","volume":"18","author":"Cendejas-Bueno","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/10428190902777434","article-title":"Invasive mold infections: recent advances in management approaches","volume":"50","author":"Chandrasekar","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.00663-08","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects","volume":"53","author":"Conte","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0045","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/JCM.01716-08","article-title":"Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia","volume":"47","author":"Cuenca-Estrella","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0065","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0070","series-title":"Guideline on validation of bioanalytical. Methods","author":"EMEA","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0075","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01407-09","article-title":"Intracellular concentrations of posaconazole in different compartments of peripheral blood","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0085","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1469-0691.2005.01262.x","article-title":"Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis","volume":"11","author":"Gavald\u00e0","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/14787210.3.4.467","article-title":"Posaconazole: clinical pharmacology and potential for management of fungal infections","volume":"3","author":"Groll","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1469-0691.2009.02913.x","article-title":"Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside","volume":"15","author":"Hope","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0110","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":"Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0115","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0120","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/AAC.01616-09","article-title":"Skin concentrations and pharmacokinetics of posaconazole after oral administration","volume":"54","author":"Krishna","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0125","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.01279-12","article-title":"Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/pharmacodynamic profile of posaconazole","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0140","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1128\/AAC.00931-09","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0150","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.44.3.727-731.2000","article-title":"Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys","volume":"44","author":"Nomeir","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0155","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jac\/dks090","article-title":"Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis","volume":"67","author":"Salas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0160","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dku023","article-title":"Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"69","author":"Siopi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0170","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.10.010_bb0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316303340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316303340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:34:09Z","timestamp":1656736449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316303340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0732889316303340"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.10.010","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}